Arcutis Announces Initiation of Phase 2a Clinical Trial of ARQ-151 as a Potential Topical Treatment for Atopic Dermatitis
ARQ-151 Potential "Best in Class" Topical PDE4 inhibitor ARQ-151 is 50- to 300-fold more potent than approved PDE4 inhibitors Phase...